Genprex, Inc. insider trading
Every open-market purchase and sale by Genprex, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $22 1 trade by 1 insider
3 months later: median −61.7% (−70.3% vs S&P 500)
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Genprex, Inc.’s insiders pay?
From April 7, 2021 to April 24, 2023, 3 insiders reported 3 open-market purchases and 0 sales not made under a pre-set plan in Genprex, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Longnecker Brent M | Director | 1 | — | — | 0 | — | April 7, 2021 |
| Vaczy Catherine M | EVP GC Chief Strategy Officer | 1 | — | — | 0 | — | April 24, 2023 |
| Varner John Rodney | Chairman, President and CEO | 1 | — | — | 0 | — | April 24, 2023 |